Akciğer Kanserli Hastalarda Pozitron Emisyon Tomografisi Görüntülerinden Elde Edilen Semikantitatif Parametrelerin Tümör Histopatolojik Özellikleri ile İlişkisi
Amaç: Bu çalışmanın amacı; akciğer kanserli hastalarda pozitron emisyon tomografisi (18F-FDG PET/BT) görüntülerinden elde edilen, tümör metabolizmasını yansıtan semikantitatif parametrelerin tümörün klinik evresi ve histopatolojik özellikleri ile ilişkisinin araştırılmasıdır. Gereç ve Yöntem: Çalışmaya 27’si adenokarsinom, 35’i epidermoid karsinom tanısı alan toplam 62 KHDAK’li hasta (E/K: 38/24; yaş ortalaması 61,29±9,5) dahil edildi. Hastaların tamamına kemo/radyoterapi öncesi F-18 FDG PET/ BT çekimi yapıldı ve SUVmax, SUVmean, metabolik tümör volümü (MTV) ve total lezyon glikolizis (TLG) değerlerinden oluşan metabolik semikantitatif parametreler hesaplandı. F-18 FDG PET/ BT metabolik parametreleri ile tümörün klinik evresi ve histopatolojik özellikleri (tümör alttipi, ki-67 indeksi) arasında bir ilişki olup olmadığı istatistiksel olarak değerlendirildi. Bulgular: Tümör evrelerine göre tüm gruplar arası SUVmax, SUVmean, MTV ve TLG değerlerinde anlamlı farklılık gözlenmedi. Tümör alt tiplerine göre yapılan analizde adenokarsinomlu hastaların SUVmax, , SUVmean, MTV ve TLG değerlerinin epidermoid karsinomlu hastalara göre istatistiksel olarak anlamlı oranda daha düşük olduğu gözlendi (p=0,003, p=0,002, p=0,002, p=0,002). Ayrıca 40 hastadan oluşan subgrupta yaptığımız histopatolojik incelemede ki-67 proliferasyon indeksi ile TLG arasında orta derecede korelasyon gözlendi (p=0.4, p=0.03). Sonuç: Küçük hücreli dışı akciğer kanserli hastalarda, F-18 FDG PET/BT metabolik parametreleri ile tümörün histopatolojik özellikleri korelasyon göstermekte olup hastalığın klinik sonuçlarını noninvaziv olarak öngörmede bu parametreler yardımcı rol oynayabilir.
___
- KAYNAKLAR
1. Vach W, Høilund-Carlsen PF, Gerke O, Weber WA.Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med. 2011;52(2):77-85.
- 2. Chierichetti F, Pizzolato G. 18F-FDG-PET/CT. Q J Nucl Med Mol Imaging. 2012;56(2):138-50.
- 3. Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005;62:545-53.
- 4. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response.J Nucl Med. 2009;50(1):88-99.
- 5. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46(6):983-95.
- 6. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27:683-87.
- 7. van Baardwijk A, Bosmans G, van Suylen RJ, van Kroonenburgh M, Hochstenbag M, Geskes G, et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol. 2008;87(1):55-8.
- 8. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008; 3(1):6-12.
9. Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS One. 2016;11:e0146195.
- 10. Hatt M, Visvikis D, Pradier O, Cheze-le Rest C. Baseline 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer. Eur J Nucl Med Mol Imaging. 2011;38:1595-606.
- 11. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122-50.
- 12. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging. 1999;2(3):159-71.
- 13. Kaim AH, von Schulthess GK. Combined functional and morphological imaging with PET/CT systems. Praxis. 2003;92(6):225-7.
- 14. Wahl RL, Jacene H, Kasamon Y, Lodge MA.From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 (1):122-50.
- 15. Duhaylongsod FG, Lowe VJ, Patz EF Jr et al. Lung tumor growth correlates with glucose matabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995;60(5):1348-52.
- 16. Vesselle H, Schmidt RA, Pugsley JM et al. Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6(10):3837-44.
- 17. Sasaki R, Komaki R, Macapinlac H et al. 18Ffluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23(6):1136-43.
- 18. Vansteenkiste JF, Stroobants SG, Dupont PJ et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17(10):3201-6.
- 19. Dhital K, Saunders CA, Seed PT et al. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000;18(4):425-8.
- 20. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998; 83:918 –24.
- 21. Sugawara Y, Quint LE, Iannettoni MD, Russo JE, Recker BE, Saran PA, Wahl RL. Does the FDG uptake of primary non-small cell lung cancer predict prognosis? A work in progress. Clin Positron Imaging. 1999; 2:111–8.
- 22. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE, Bastian P, Vallie' res ASE, Wood DE. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role. Clin Cancer Res. 2007; 13(11):3255 - 63.
- 23. Bing B, Bading J, Conti PS. Tumor quantification in clinical positron emission tomography. Theranostic. 2013; 3(10):787-801.
- 24. Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78.
- 25. Hatt M, Visvikis D, Pradier O, Cheze-le Rest C. Baseline ¹⁸F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer. Eur J Nucl Med Mol Imaging. 2011;38(9):1595-606.
- 26. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-22.
- 27. Jakobsen JN, Sørensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer. 2013;79(1):1-7.
- 28. Pugsley JM1, Schmidt RA, Vesselle H. The Ki-67 index and survival in non-small cell lung cancer: a review and relevance to positron emission tomography. Cancer J. 2002;8(3):222-33.
- 29. Nakamura H, Hirata T, Kitamura H, Nishikawa J. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers. Ann Thorac Cardiovasc Surg. 2009;15(5):304-10.